Journal
CLINICAL CANCER RESEARCH
Volume 27, Issue 16, Pages 4462-4464Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-1750
Keywords
-
Categories
Funding
- Italian Ministry of Health, Rome, Italy [PE-201602362756, RF-2018-12365790]
- Associazione Italiana Ricerca Cancro (AIRC) [IG-21687]
- Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore/Veneto Orientale Group, Italy
- 5 x 1000 Intramural Program, Centro di Riferimento Oncologico, Aviano, Italy
Ask authors/readers for more resources
Patients with chronic lymphocytic leukemia carrying a single TP53 hit (chromosome 17p deletion or single TP53 mutation) show better survival outcomes on ibrutinib therapy compared to those with multiple TP53 hits. Testing for TP53 deletion/mutation using a combination of FISH and deep next-generation sequencing is recommended for accurate patient evaluation.
Patients with chronic lymphocytic leukemia carrying a single TP53 hit (chromosome 17p deletion or single TP53 mutation) demonstrate excellent progression-free survival and overall survival on ibrutinib compared with cases harboring multiple TP53 hits. Testing TP53 deletion/mutation combining FISH and deep nextgeneration sequencing should be performed for a correct patient evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
